Announcing a new article publication for BIO Integration journal. Cardiac cell death and myocardial fibrosis after ischemia-reperfusion (I/R) injury are the primary causes of impaired cardiac function ...

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. wants in—penning a $1.9 billion biobucks deal to collaborate on new therapies for ...

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...